Cellosaurus NK-92MIhCD16 (CVCL_JX95)
| Cell line name | NK-92MIhCD16 |
|---|---|
| Accession | CVCL_JX95 |
| Resource Identification Initiative | To cite this cell line use: NK-92MIhCD16 (RRID:CVCL_JX95) |
| Comments | Population: Caucasian. Characteristics: Transfected with the CD16-BB-zeta construct that consist of a signal peptide, the FCGR3/CD16A extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD247/CD3Z signaling domain. Genetic integration: Method=Transfection/transduction; Gene=HGNC; 3619; FCGR3A (Note=Extracellular domain). Genetic integration: Method=Transfection/transduction; Gene=HGNC; 6001; IL2. Caution: NantKwest exclusively owns, controls and distributes NK-92MI. This CD16-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party. Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. Cell type: Natural killer cell; CL=CL_0000623. |
| Disease | Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217) |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy | Parent: CVCL_3755 (NK-92MI) |
| Sex of cell | Male |
| Age at sampling | 50Y |
| Category | Cancer cell line |
| Publications | PubMed=28415754; DOI=10.18632/oncotarget.16201; PMCID=PMC5514896 |
| Cross-references | |
| Encyclopedic resources | Wikidata; Q54930659 |
| Entry history | |
| Entry creation | 22-Aug-2017 |
| Last entry update | 10-Sep-2024 |
| Version number | 9 |